<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355f" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355f/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355f/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355f"><akn:num>355f</akn:num><akn:heading>Extension of exclusivity period for new qualified infectious disease products</akn:heading><akn:content><akn:p>§ 355f. Extension of exclusivity period for new qualified infectious disease products(a) ExtensionIf the Secretary approves an application pursuant to section 355 of this title for a drug that has been designated as a qualified infectious disease product under subsection (d), the 4- and 5-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 355 of this title, the 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 355 of this title, or the 7-year period described in section 360cc of this title, as applicable, shall be extended by 5 years.


(b) Relation to pediatric exclusivityAny extension under subsection (a) of a period shall be in addition to any extension of the period under section 355a of this title with respect to the drug.


(c) LimitationsSubsection (a) does not apply to the approval of—(1) a supplement to an application under section 355(b) of this title for any qualified infectious disease product for which an extension described in subsection (a) is in effect or has expired;

(2) a subsequent application filed with respect to a product approved under section 355 of this title for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength;

(3) a product that does not meet the definition of a qualified infectious disease product under subsection (g) based upon its approved uses; or

(4) an application pursuant to section 262(a) of title 42.


(d) Designation(1) In generalThe manufacturer or sponsor of a drug may request the Secretary to designate a drug as a qualified infectious disease product at any time before the submission of an application under section 355(b) of this title or section 262(a) of title 42 for such drug. The Secretary shall, not later than 60 days after the submission of such a request, determine whether the drug is a qualified infectious d</akn:p></akn:content><akn:subsection eId="subsec_355f_a"><akn:num>(a)</akn:num><akn:heading>Extension</akn:heading><akn:content><akn:p>(a) Extension If the Secretary approves an application pursuant to section 355 of this title for a drug that has been designated as a qualified infectious disease product under subsection (d), the 4- and 5-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 355 of this title, the 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 355 of this title, or the 7-year period described in section 360cc of this title, as applicable, shall be extended by 5 years.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_b"><akn:num>(b)</akn:num><akn:heading>Relation to pediatric exclusivity</akn:heading><akn:content><akn:p>(b) Relation to pediatric exclusivity Any extension under subsection (a) of a period shall be in addition to any extension of the period under section 355a of this title with respect to the drug.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_c"><akn:num>(c)</akn:num><akn:heading>Limitations</akn:heading><akn:content><akn:p>(c) Limitations Subsection (a) does not apply to the approval of—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_d"><akn:num>(d)</akn:num><akn:heading>Designation</akn:heading><akn:content><akn:p>(d) Designation</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_e"><akn:num>(e)</akn:num><akn:heading>Regulations</akn:heading><akn:content><akn:p>(e) Regulations</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_f"><akn:num>(f)</akn:num><akn:heading>Qualifying pathogen</akn:heading><akn:content><akn:p>(f) Qualifying pathogen</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355f_g"><akn:num>(g)</akn:num><akn:heading>Qualified infectious disease product</akn:heading><akn:content><akn:p>(g) Qualified infectious disease product The term “qualified infectious disease product” means a drug (including a biological product), including an antibacterial or antifungal drug, for human use that—</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>